证券代码：000788 证券简称：北大医药 公告编号：2025-056 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司 第十一届监事会第八次会议决议公告 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届监事会第八次会议于 2025 年 8 月 20 日上午在北京市昌平区生命科学园北大医疗创新谷 6 号楼 3 层会 议室以现场结合通讯方式召开。会议通知于 2025 年 8 月 8 日以传真、电子邮件 或送达方式发给各位监事。本次会议应出席监事 5 人，实际出席监事 5 人。其中 监事张必成先生、李孝伦先生、郑晓东先生、程琴女士、游菊女士以通讯方式参 加会议。本次会议由监事会主席张必成先生主持，公司监事会秘书、部分高级管 理人员列席了本次会议。会议的召开符合《中华人民共和国公司法》《公司章程》 等有关规定。 二、会议审议情况 1、审议通过《2025 年半年度报告全文及摘要》 公司董事会对公司 2025 年半年度的实际经营情况进行了总结，并编制了公 司 2025 年 半 年 度 报 告 及 摘 要 。 相 关 内 容 参 见 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-055 北大医药股份有限公司 第十一届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届董事会第十三次会议 于 2025 年 8 月 20 日上午在北京市昌平区生命科学园北大医疗创新谷 6 号楼 3 层会议室以现场结合通讯方式召开。会议通知于 2025 年 8 月 8 日以传真、电子 邮件或送达方式发给各位董事。本次会议应出席董事 8 人，实际出席董事 8 人。 其中董事包铁民先生、黄联军先生、王唯宁先生、贾剑非女士以通讯方式参加会 议，其余董事出席现场会议。本次会议由董事长徐晰人先生主持，公司部分监事、 高级管理人员列席了本次会议。会议的召开符合《中华人民共和国公司法》《公 司章程》等有关规定。 二、会议审议情况 1、审议通过《2025 年半年度报告全文及摘要》 派发红利 17,879,622.75 元（含税），本次利润分配不送红股，不以资本公积金 转增股本。若在分配预案实施前，公司总股本由于可转债、股份 ...

北大医药股份有限公司 2025 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 北大医药股份有限公司 公司负责人徐晰人、主管会计工作负责人赵全波及会计机构负责人(会计 主管人员)赵全波声明：保证本半年度报告中财务报告的真实、准确、完整。 2025 年半年度报告 所有董事均已出席了审议本次半年报的董事会会议。 【2025 年 8 月】 本报告中如有涉及未来计划、业绩预测等方面的前瞻性陈述，均不构成 公司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风险。 1 北大医药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司未来经营发展受各种风险因素影响，公司在本报告第三节"管理层 讨论与分析"之"十、公司面临的风险和应对措施"中描述了公司可能面临 的风险和应对措施，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 595,987,425 股为基 数，向全体股东每 10 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-057 北大医药股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 1、董事会审议情况 北大医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十三次会议，以 8 票同意，0 票反对，0 票回避，0 票弃权的表决 结果审议通过了《2025 年半年度利润分配预案》。 2、监事会审议情况 公司于 2025 年 8 月 20 日召开第十一届监事会第八次会议，以 5 票同意，0 票反对，0 票回避，0 票弃权的表决结果审议通过了《2025 年半年度利润分配预 案》。 3、独立董事专门会议审议情况 公司独立董事于 2025 年 8 月 19 日召开第十一届董事会独立董事专门会议第 七次会议，以 3 票同意，0 票反对，0 票弃权的表决结果审议通过了《2025 年半 年度利润分配预案》。 公司独立董事核查后认为，公司 2025 年半年度利润分配预案综合考虑了公 司发展战略、盈利前景、未来资金使用需求、资 ...

Group 1 - The company's operating revenue for the first half of 2025 is 957 million yuan, representing a year-on-year decrease of 5.04% [1] - The net profit for the same period is 100 million yuan, showing a year-on-year increase of 15.51% [1]

Core Viewpoint - The company faces significant risks due to the termination of its business cooperation with Peking University International Hospital, which has been its primary customer, leading to a potential loss of nearly half of its revenue and profit starting from 2026 [2][3]. Group 1: Business Impact - The termination of cooperation with the International Hospital has resulted in the cessation of the main business of the company's subsidiary, Beijing Beiyi Pharmaceutical, since June 2023 [2][3]. - The company anticipates a revenue decrease of approximately 600 million yuan (about 29.13% of the latest audited revenue) and a net profit reduction of around 40 million yuan (about 28.99% of the latest audited net profit) for the year [3]. - Starting from 2026, the company may face even greater losses, with a projected revenue decline of 1.027 billion yuan and a net profit decrease of approximately 68.69 million yuan, which could account for nearly 50% of the company's latest audited revenue and net profit [3]. Group 2: Business Transition - The company is attempting to shift its resources towards pharmaceutical manufacturing, establishing a new subsidiary focused on production to enhance its capabilities in generic drug manufacturing [2][6]. - The company has undergone changes in its actual controlling shareholder, moving away from Peking University, and is planning to gradually change the names of the company and its subsidiaries to reflect this shift [5][6]. Group 3: Financial Performance - In 2024, the company's pharmaceutical distribution business generated revenue of 1.437 billion yuan, accounting for 69.75% of total revenue, with an operating profit of 194 million yuan, representing 35.05% of the total [4]. - The pharmaceutical manufacturing revenue for 2024 was 623 million yuan, making up about 30% of total revenue, with a gross margin of 57.47%, significantly higher than the 13.48% gross margin of the distribution business [7].

Group 1 - The Ministry of Finance, the People's Bank of China, and the Financial Regulatory Bureau issued a policy to provide a 1% annual interest subsidy for personal consumption loans under certain conditions, covering seven key areas including home appliances, automotive, and education, effective from September 1, 2025, to August 31, 2026 [8][9]. - China Evergrande announced that it received a letter from the Hong Kong Stock Exchange stating that its listing status would be canceled due to failure to meet the resumption requirements, with the last trading day set for August 22, 2025 [30][31]. - The U.S. Labor Department reported that the Consumer Price Index (CPI) increased by 0.2% month-on-month in July, with a year-on-year increase of 2.7%, while core CPI rose by 0.3% month-on-month and 3.1% year-on-year [3]. Group 2 - The U.S. and China agreed to extend the "truce period" on tariffs for an additional 90 days, with both sides suspending the implementation of 24% tariffs on each other's goods [5][6]. - Micron Technology announced it would cease the development of future mobile NAND products globally due to ongoing market weakness, while continuing to support other NAND solutions [21][22]. - China Unicom reported a revenue of over 200 billion yuan for the first half of the year, marking a 1.5% year-on-year increase, with a pre-tax profit of 17.8 billion yuan, up 5.1% [24][25]. Group 3 - The Chinese Nonferrous Metals Industry Association's lithium division called for a halt to "involutionary" competition in the lithium industry, urging companies to maintain fair competition and avoid market monopolization [10]. - Huawei announced the release of its AI inference innovation technology UCM, which will be open-sourced in September, aimed at enhancing AI performance [23]. - North University Pharmaceutical faced significant revenue loss after terminating its partnership with its largest client, Beijing University International Hospital, which accounted for 78.15% of its drug distribution revenue [32][33].

Core Viewpoint - The company faces significant risks due to the termination of its business cooperation with Peking University International Hospital, which is its largest customer, leading to a potential complete halt of its main business operations [1][4]. Group 1: Business Impact - The termination of the partnership with the International Hospital has resulted in a projected revenue decrease of approximately 600 million yuan for the company this year, which accounts for 29.13% of its most recent audited revenue [4]. - The company anticipates a net profit reduction of about 40 million yuan, representing 28.99% of its latest audited net profit [4]. - Starting in 2026, the company could face even more severe losses, with a potential revenue drop of 1.027 billion yuan and a net profit decrease of around 68.69 million yuan, which would account for nearly 50% of its recent audited revenue and net profit [4]. Group 2: Revenue Sources - In 2024, the company's pharmaceutical distribution business generated revenue of 1.437 billion yuan, making up 69.75% of total revenue, with an operating profit of 194 million yuan, accounting for 35.05% [5]. - The International Hospital's actual procurement amount for 2024 was 1.123 billion yuan, which constituted 78.15% of the company's pharmaceutical distribution revenue [6]. Group 3: Strategic Shift - The company is attempting to shift its resources towards pharmaceutical manufacturing, establishing a new subsidiary focused on production to enhance its capabilities in generic drug manufacturing [1][7]. - The company has undergone changes in its actual controlling shareholder, moving away from Peking University, and is planning to gradually change its name to reflect this shift [7]. - In 2024, the company's pharmaceutical manufacturing revenue was 623 million yuan, representing about 30% of total revenue, with a gross margin of 57.47%, significantly higher than the 13.48% gross margin of its pharmaceutical distribution business [7][8].

Core Viewpoint - The business cooperation between Beijing Beiyi Pharmaceutical and Peking University International Hospital is nearing completion, leading to potential risks of business cessation, personnel layoffs, and corporate transformation for Beiyi Pharmaceutical [1][2]. Group 1: Business Overview - Beijing Beiyi Pharmaceutical, a wholly-owned subsidiary of Beida Pharmaceutical, is primarily engaged in the distribution, retail, hospital procurement, and pharmacy management of third-party drugs, medical devices, and consumables [1]. - The contract between Beiyi Pharmaceutical and Peking University International Hospital, which was effective from May 2022 to May 2023, has expired, and both parties will not continue their cooperation, significantly impacting the revenue of both companies [2][4]. Group 2: Financial Impact - The loss of Peking University International Hospital as a client could lead to a significant revenue decline for Beiyi Pharmaceutical, with an estimated sales revenue reduction of approximately 600 million yuan, accounting for about 29.13% of the company's latest audited revenue [5]. - Beiyi Pharmaceutical's total revenue for 2024 is projected to be 2.06 billion yuan, with around 50% of this revenue dependent on the contract with the hospital [4][5]. - If the cooperation is completely terminated, Beiyi Pharmaceutical's profitability could shrink by nearly half, with a potential revenue decrease of about 1.027 billion yuan starting in 2026 [5]. Group 3: Market Reaction - On August 12, the stock price of Beida Pharmaceutical fell by over 9%, closing at 6.42 yuan per share, a decline of 7.36%, with a total market capitalization of 3.826 billion yuan [1]. Group 4: Industry Context - The situation reflects a typical case of over-reliance on a single major client, which can lead to severe financial consequences when the partnership ends [6]. - The healthcare industry is experiencing rapid changes, including accelerated medical reforms and centralized procurement, which may further compress traditional distribution margins [6].

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交7848.40万元，其中，买入成交额为 3971.77万元，卖出成交额为3876.63万元，合计净买入95.13万元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买一、买二、买三、买五、卖一、卖 二、卖四，合计买入金额3385.01万元，卖出金额2631.64万元，合计净买入753.37万元。 资金流向方面，今日该股主力资金净流出3527.48万元，其中，特大单净流出1611.16万元，大单资金净 流出1916.31万元。近5日主力资金净流出6597.05万元。（数据宝） 北大医药今日下跌7.36%，全天换手率11.13%，成交额4.26亿元，振幅6.71%。龙虎榜数据显示，机构净 买入753.37万元，营业部席位合计净卖出658.23万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-7.69%上榜，机构专用席位净买入753.37万元。 北大医药8月12日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 1225 ...